No data to show
XKRX
287410
Market cap714mUSD
Oct 18, Last price
12,900.00KRW
Name
Jeisys Medical Inc
Chart & Performance
P/E
39.30
P/S
6.81
EPS
328.22
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
143.03b
Net income
24.80b
CFO
32.68b
Profile
Jeisys Medical Inc. designs, develops, and manufactures medical device for plastic surgeons, dermatologist, physicians, and healthcare professionals in South Korea and internationally. The company offers products for treatment areas, such as skin rejuvenation, lifting/tightening, pigmentation treatments, fat reduction, acne, tattoo removal, and scars and striae distensae under the ULTRAcel Q+ system, Cellec V system, LIPOcel, AcGen, TRI-BEAM Premium, Edge ONE, SmoothCool, and ULTRAcel brands. It provides its products through a network of distributors. The company was founded in 2001 and is based in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY |
|---|---|
| 2023‑12 | |
| Income | |
Revenues | 143,029,553 |
Cost of revenue | 75,420,748 |
Unusual Expense (Income) | |
NOPBT | 67,608,805 |
NOPBT Margin | 47.27% |
Operating Taxes | 10,390,441 |
Tax Rate | 15.37% |
NOPAT | 57,218,363 |
Net income | 24,800,415 |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | (2,224,811) |
BB yield | |
| Debt | |
Debt current | 3,335,554 |
Long-term debt | 24,899,816 |
Deferred revenue | |
Other long-term liabilities | 273,377 |
Net debt | (30,123,286) |
| Cash flow | |
Cash from operating activities | 32,677,913 |
CAPEX | (15,017,612) |
Cash from investing activities | (17,659,795) |
Cash from financing activities | (5,092,360) |
FCF | |
| Balance | |
Cash | 48,830,207 |
Long term investments | 9,528,448 |
Excess cash | 51,207,178 |
Stockholders' equity | 80,243,253 |
Invested Capital | 70,921,861 |
ROIC | 80.68% |
ROCE | 55.36% |
| EV | |
Common stock shares outstanding | 77,020 |
Price | |
Market cap | |
EV | |
EBITDA | 71,872,280 |
EV/EBITDA | |
Interest | 222,439 |
Interest/NOPBT | 0.33% |